Stock Events

CASI Pharmaceuticals 

$2.67
35
-$0.19-6.64% Tuesday 19:59

Statistics

Day High
2.84
Day Low
2.61
52W High
8.48
52W Low
1.9
Volume
10,241
Avg. Volume
17,711
Mkt Cap
35.78M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

28MarConfirmed
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-1.44
-1.04
-0.64
-0.24
Expected EPS
-0.24
Actual EPS
-0.45

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CASI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.86B
BioMarin Pharmaceutical Inc. focuses on developing and commercializing innovative therapies for rare diseases, a market CASI Pharmaceuticals also targets, making them direct competitors in the niche pharmaceutical sector.
Alnylam Pharmaceuticals
ALNY
Mkt Cap20.29B
Alnylam Pharmaceuticals, Inc. specializes in RNAi (RNA interference) therapeutics for the treatment of rare genetic diseases, competing with CASI Pharmaceuticals in the rare disease drug market.
Vertex Pharmaceuticals
VRTX
Mkt Cap124.05B
Vertex Pharmaceuticals Incorporated is known for its focus on treating cystic fibrosis and other serious diseases, competing with CASI Pharmaceuticals in the market for treatments for rare diseases.
Incyte
INCY
Mkt Cap13.95B
Incyte Corporation has a strong focus on oncology, including therapies for rare cancers, which puts it in direct competition with CASI Pharmaceuticals' cancer treatment portfolio.
Exelixis
EXEL
Mkt Cap6.33B
Exelixis, Inc. is focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers, competing with CASI Pharmaceuticals in the oncology market.
Bluebird bio
BLUE
Mkt Cap104.92M
bluebird bio, Inc. focuses on gene therapies for severe genetic diseases and cancer, competing with CASI Pharmaceuticals in the innovative treatment market for rare diseases.
Novartis
NVS
Mkt Cap231.52B
Novartis AG, a large pharmaceutical company, has a broad portfolio that includes treatments for rare diseases and cancer, making it a competitor to CASI Pharmaceuticals due to its scale and breadth of research.
Gilead Sciences
GILD
Mkt Cap81.06B
Gilead Sciences, Inc. is involved in the discovery, development, and commercialization of innovative therapeutics in areas including oncology, competing with CASI Pharmaceuticals in the cancer treatment space.
AMGEN
AMGN
Mkt Cap160.19B
Amgen Inc. has a diverse portfolio of treatments, including for rare diseases and cancer, making it a competitor to CASI Pharmaceuticals with its broad focus on innovative therapeutic solutions.

Analyst Ratings

6$Average Price Target
The highest estimate is $6.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Show more...
CEO
Wei-Wu He
Employees
176
Country
US
ISIN
US14757U1097
WKN
000A3DM91

Listings